Cure My Disease

Don't miss your cure!

 Log in / Sign up

New CAR T-Cell therapy aims to wipe out hidden leukemia cells

NCT ID NCT06144606

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests KTE-X19 (Tecartus), a personalized CAR T-cell therapy, in adults with B-cell acute lymphoblastic leukemia who are in remission but still have tiny amounts of cancer cells (minimal residual disease). The goal is to see if this treatment can clear those leftover cells and prevent relapse. About 60 participants will receive the therapy, and researchers will track how long they stay cancer-free.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
KTE-X19 (Tecartus), a CAR T-cell therapy made from the patient's own immune cells
What this could lead to
If successful, this could offer a way to eliminate remaining leukemia cells in patients who are in remission, potentially preventing relapse and improving long-term outcomes.
What could go wrong
This is a mid-stage trial with only 60 participants, so results may not apply to everyone. CAR T-cell therapy can cause serious side effects like cytokine release syndrome and neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia Burkitt lymphoma precursor B-cell acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE LYMPHOBLASTIC LEUKEMIA B-CELL LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.